In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
PREGNANCY: Mobocertinib can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with mobocertinib and for 1 month after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with mobocertinib and for 1 week after the last dose.
MOBOCERTINIB CAN CAUSE LIFE-THREATENING HEART RATE-CORRECTED QT (QTC) PROLONGATION, INCLUDING TORSADES DE POINTES, WHICH CAN BE FATAL, AND REQUIRES MONITORING OF QTC AND ELECTROLYTES AT BASELINE AND PERIODICALLY DURING TREATMENT. INCREASE MONITORING FREQUENCY IN PATIENTS WITH RISK FACTORS FOR QTC PROLONGATION AVOID USE OF CONCOMITANT DRUGS WHICH ARE KNOWN TO PROLONG THE QTC INTERVAL AND THE USE OF STRONG OR MODERATE CYP3A INHIBITORS WITH MOBOCERTINIB, WHICH MAY FURTHER PROLONG THE QTC. WITHHOLD, REDUCE THE DOSE, OR PERMANENTLY DISCONTINUE MOBOCERTINIB BASED ON THE SEVERITY OF QTC PROLONGATION.
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.